Residual Disease and Immune Infiltration as a New Surrogate Endpoint for TNBC Post Neoadjuvant Chemotherapy

Oncotarget - United States
doi 10.18632/oncotarget.27081
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Impact Journals, LLC


Related search